In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.

The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A total of ...

Why settle for a mundane daily driver when you can infuse excitement into your routine with a sports car? The dominance of crossovers in America makes it easy to forget the joys of driving a two-door ...